AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.38 USD
-0.52 (-0.66%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $78.50 +0.12 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for AstraZeneca PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 6,078 | 6,492 | 6,481 | 8,134 | 6,254 |
Receivables | 13,552 | 11,252 | 10,307 | 7,386 | 6,046 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,424 | 4,699 | 8,983 | 4,024 | 3,193 |
Other Current Assets | 0 | 150 | 473 | 0 | 70 |
Total Current Assets | 25,054 | 22,593 | 26,244 | 19,544 | 15,563 |
Net Property & Equipment | 9,402 | 8,507 | 9,183 | 8,251 | 7,688 |
Investments & Advances | 1,905 | 1,216 | 1,339 | 1,318 | 1,520 |
Other Non-Current Assets | 803 | 835 | 895 | 720 | 740 |
Deferred Charges | 4,718 | 3,263 | 4,330 | 3,438 | 2,718 |
Intangibles | 58,137 | 59,127 | 62,384 | 32,792 | 32,501 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 101,119 | 96,483 | 105,363 | 66,729 | 61,377 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 22,374 | 19,040 | 18,938 | 15,785 | 13,987 |
Current Portion Long-Term Debt | 5,129 | 5,314 | 1,660 | 2,194 | 1,822 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1,584 | 896 | 916 | 1,127 | 1,361 |
Other Current Liabilities | 1,184 | 815 | 847 | 1,009 | 759 |
Total Current Liabilities | 30,542 | 26,293 | 22,594 | 20,307 | 18,117 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2,844 | 2,944 | 6,206 | 2,918 | 2,490 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 22,365 | 22,965 | 28,134 | 17,505 | 15,730 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5,345 | 6,498 | 8,388 | 9,872 | 9,957 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 61,953 | 59,425 | 66,076 | 51,091 | 46,781 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 388 | 387 | 387 | 328 | 328 |
Capital Surplus | 35,188 | 35,155 | 35,126 | 7,971 | 7,941 |
Retained Earnings | 1,502 | -574 | 1,710 | 5,299 | 2,812 |
Other Equity | 2,088 | 2,090 | 2,064 | 2,040 | 3,515 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 39,166 | 37,058 | 39,287 | 15,638 | 14,596 |
Total Liabilities & Shareholder's Equity | 101,119 | 96,483 | 105,363 | 66,729 | 61,377 |
Total Common Equity | 39,166 | 37,058 | 39,287 | 15,638 | 14,596 |
Shares Outstanding | 3,100.30 | 3,099.60 | 3,098.80 | 2,624.50 | 2,623.70 |
Book Value Per Share | 12.63 | 11.96 | 12.68 | 5.96 | 5.56 |
Fiscal Year End for AstraZeneca PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7,104 | 8,032 | 6,078 | 5,212 | 5,812 |
Receivables | 12,622 | 12,225 | 13,552 | 11,997 | 11,932 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5,667 | 5,337 | 5,424 | 5,292 | 5,051 |
Other Current Assets | 0 | 0 | 0 | 0 | 44 |
Total Current Assets | 25,393 | 25,594 | 25,054 | 22,501 | 22,839 |
Net Property & Equipment | 9,630 | 9,411 | 9,402 | 8,723 | 8,675 |
Investments & Advances | 2,088 | 1,908 | 1,905 | 1,441 | 1,143 |
Other Non-Current Assets | 806 | 745 | 803 | 761 | 752 |
Deferred Charges | 4,734 | 4,618 | 4,718 | 4,057 | 3,736 |
Intangibles | 60,486 | 58,812 | 58,137 | 57,626 | 58,286 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 163 |
Total Assets | 104,340 | 102,293 | 101,119 | 96,086 | 96,543 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 20,463 | 19,699 | 22,374 | 20,542 | 19,738 |
Current Portion Long-Term Debt | 5,067 | 6,050 | 5,129 | 5,372 | 4,556 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1,525 | 1,631 | 1,584 | 1,163 | 1,200 |
Other Current Liabilities | 1,219 | 1,240 | 1,184 | 1,276 | 650 |
Total Current Liabilities | 28,566 | 28,901 | 30,542 | 28,588 | 26,375 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3,333 | 2,621 | 2,844 | 2,752 | 2,800 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 27,225 | 27,259 | 22,365 | 22,225 | 24,329 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4,669 | 5,345 | 4,556 | 4,901 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 64,742 | 64,792 | 61,953 | 58,865 | 59,127 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 388 | 388 | 388 | 387 | 387 |
Capital Surplus | 35,199 | 35,194 | 35,188 | 35,166 | 35,163 |
Retained Earnings | 1,847 | -212 | 1,502 | -434 | -234 |
Other Equity | 2,164 | 2,131 | 2,088 | 2,102 | 2,100 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 39,598 | 37,501 | 39,166 | 37,221 | 37,416 |
Total Liabilities & Shareholder's Equity | 104,340 | 102,293 | 101,119 | 96,086 | 96,543 |
Total Common Equity | 39,598 | 37,501 | 39,166 | 37,221 | 37,416 |
Shares Outstanding | 3,100.50 | 3,100.40 | 3,100.30 | 3,099.80 | 3,099.70 |
Book Value Per Share | 12.77 | 12.10 | 12.63 | 12.01 | 12.07 |